Media coverage
BioCentury Emerging Company Profile: Artios: Probing DNA Damage

Artios is attacking a different DNA Damage Response pathway that could be more selective than PARP inhibitors. https://www.biocentury.com/biocentury/emerging-company-profile/2019-01-11/how-artios-attacking-different-dna-damage-response-

30 January 2019
Read more
Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors’ Andrew Scott sits down with Arix Bioscience Plc’s (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma to discuss the Series B financing. https://www.proactiveinvestors.co.uk/companies/stocktube/10188/artios-in-strong-position-to-accelerate-cancer-programmes-after-arix-investment-10188.html  

19 December 2018
Read more
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023. https://scrip.pharmaintelligence.informa.com/SC123568/Artios-Pharma-Hooks-Novartis–Pfizer-In-OverSubscribed-65M-Series-B-Round  

19 December 2018
Read more
Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017. […]

23 October 2018
Read more
Interview with Artios’ CEO following Biotech and Money’s Awards 2017

Artios Pharma scooped two awards at the Biotech and Money Awards 2017. The DNA Damage Response company was named winner in the UK Life Science Young Company of the Year (1-3 years old) category and the UK Private Finance Raise of the Year (≤£25 million) category. Biotech and Money spoke to Artios Pharma’s Chief Executive […]

16 November 2017
Read more